CAPRANZANO, PIERA
 Distribuzione geografica
Continente #
NA - Nord America 8.432
AS - Asia 3.908
EU - Europa 2.616
SA - Sud America 672
AF - Africa 436
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 5
Totale 16.075
Nazione #
US - Stati Uniti d'America 8.153
SG - Singapore 2.008
CN - Cina 1.276
IE - Irlanda 859
UA - Ucraina 593
BR - Brasile 582
IT - Italia 447
CI - Costa d'Avorio 330
VN - Vietnam 296
CA - Canada 240
RU - Federazione Russa 199
SE - Svezia 127
KR - Corea 99
GB - Regno Unito 77
FR - Francia 65
DE - Germania 61
IN - India 59
SN - Senegal 43
NL - Olanda 36
AR - Argentina 34
BD - Bangladesh 30
MX - Messico 25
UZ - Uzbekistan 24
ZA - Sudafrica 24
AT - Austria 23
PL - Polonia 22
IQ - Iraq 21
ES - Italia 20
BE - Belgio 19
CH - Svizzera 18
FI - Finlandia 17
EC - Ecuador 16
HK - Hong Kong 14
GR - Grecia 12
ID - Indonesia 12
BJ - Benin 10
IR - Iran 10
TR - Turchia 10
VE - Venezuela 10
JP - Giappone 9
MA - Marocco 9
PK - Pakistan 8
UY - Uruguay 8
PE - Perù 6
CO - Colombia 5
EU - Europa 5
KE - Kenya 5
PY - Paraguay 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
NG - Nigeria 4
NP - Nepal 4
RS - Serbia 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
BG - Bulgaria 3
EG - Egitto 3
JO - Giordania 3
OM - Oman 3
AL - Albania 2
AU - Australia 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BO - Bolivia 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
HN - Honduras 2
LB - Libano 2
LT - Lituania 2
SA - Arabia Saudita 2
TV - Tuvalu 2
BA - Bosnia-Erzegovina 1
BY - Bielorussia 1
BZ - Belize 1
CY - Cipro 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GA - Gabon 1
GH - Ghana 1
IL - Israele 1
IM - Isola di Man 1
JM - Giamaica 1
KG - Kirghizistan 1
KI - Kiribati 1
KN - Saint Kitts e Nevis 1
KW - Kuwait 1
KZ - Kazakistan 1
LC - Santa Lucia 1
MT - Malta 1
NI - Nicaragua 1
NO - Norvegia 1
PH - Filippine 1
PR - Porto Rico 1
PT - Portogallo 1
RO - Romania 1
SV - El Salvador 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 16.075
Città #
Dallas 1.439
Santa Clara 1.130
Singapore 867
Dublin 859
Jacksonville 803
Chandler 684
Houston 500
Boardman 401
Abidjan 330
Ashburn 272
Nanjing 245
Hefei 241
Chicago 237
Andover 214
Cambridge 213
Lawrence 213
Toronto 171
Catania 141
Des Moines 141
Beijing 133
Dong Ket 125
Los Angeles 107
Civitanova Marche 105
Seoul 99
Nanchang 83
Wilmington 83
San Mateo 76
Hebei 63
Ho Chi Minh City 59
Shenyang 52
São Paulo 51
Ottawa 48
Hanoi 47
Jiaxing 47
Saint Petersburg 45
Dakar 43
Council Bluffs 41
Tianjin 39
Changsha 38
The Dalles 37
Columbus 34
Bremen 31
Buffalo 31
Washington 31
New York 26
Moscow 24
Rio de Janeiro 22
Amsterdam 21
Brooklyn 21
Norwalk 21
Pune 21
Seattle 21
Phoenix 20
Brussels 19
Kunming 17
Ningbo 17
Falls Church 16
Hangzhou 16
Belo Horizonte 15
San Francisco 15
Helsinki 14
Jinan 14
Milan 14
Redondo Beach 14
Boston 13
Hong Kong 13
Guangzhou 12
Johannesburg 12
London 12
Den Haag 11
Stockholm 11
Warsaw 11
Atlanta 10
Cotonou 10
Denver 9
Haiphong 9
Santos 9
Tokyo 9
Zhengzhou 9
Baghdad 8
Curitiba 8
Da Nang 8
Dhaka 8
Liberty Lake 8
Mumbai 8
Porto Alegre 8
Tehran 8
Ann Arbor 7
Brasília 7
Charlotte 7
Edinburgh 7
Montevideo 7
Montreal 7
Palermo 7
Santo André 7
Chennai 6
Elk Grove Village 6
Guarulhos 6
Guayaquil 6
Hortolândia 6
Totale 11.327
Nome #
Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: A meta-analysis of 50,578 patients 531
1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds versus Everolimus-Eluting Stents: a Propensity Matched Comparison of the GHOST-EU and XIENCE V USA Registries 173
A Risk Model for Prediction of One-Year Mortality in Patients Undergoing MitraClip Implantation 148
1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry 131
A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score 121
Anatomical features and management of bioresorbable vascular scaffolds failure: A case series from the GHOST registry. 116
Platelet function profiles in the elderly: Results of a pharmacodynamic study in patients on clopidogrel therapy and effects of switching to prasugrel 5 mg in patients with high platelet reactivity. 112
A comparison between Endeavor and Endeavor Resolute drug-eluting stents: outcome at six months follow up 109
Early cardiovascular remodelling in Fabry disease 106
Incidence, Timing, Causes and Predictors of Early and Late Re-Hospitalization in Patients Who Underwent Percutaneous Mitral Valve Repair With the MitraClip System 104
The treatment of coronary bifurcation lesions with bioresorbable vascular scaffolds 102
Cigarette Smoking is Associated with a Dose-Response Effect in Clopidogrel Treated Patients with Diabetes Mellitus and Coronary Artery Disease: Results of a Pharmacodynamic Study 102
Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement 101
A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. 101
A comparison between Endeavor and Endeavor Resolute drug-eluting coronary stents: outcomes at six month follow up 100
Effect of post-procedural evidence-based therapy on 2-year prognosis after transcatheter mitral valve repair 99
A post-hoc analysis of the CUSTOMIZE Registry on the differential impact of EuroSCORE and SYNTAX score in Left Main Patients with Intermediate Global Risk 97
Clinical Outcomes Following Intravascular Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary Intervention With Stent Implantation: A Systematic Review and Bayesian Network Meta-Analysis of 31 Studies and 17,882 Patients 97
Acute Left Atrial Spontaneous Echo Contrast and Suspicious Thrombus Formation Following Mitral Regurgitation Reduction With The MitraClip System 96
Acute and 30-Day Outcomes in Women After TAVR: Results From the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation) Real-World Registry 95
Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve Failure After Transcatheter Aortic Valve Replacement 95
Current status of transcatheter valve therapy in Europe: results from an EAPCI survey 91
Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation) 91
Association of Tricuspid Regurgitation With Clinical and Echocardiographic Outcomes After Percutaneous Mitral Valve Repair With the MitraClip System: Thirty-Day and Twelve-Month Follow-up From the GRASP Registry 89
Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization: A Post Hoc Analysis of the DELTA Registry 89
Comparison of suture-based vascular closure devices in transfemoral transcatheter aortic valve implantation. 89
Vascular response and healing profile of everolimus-eluting bioresorbable vascular scaffolds for percutaneous treatment of chronic total coronary occlusions: A one-year optical coherence tomography analysis from the GHOST-CTO registry 89
Clinical implication of different plaque distribution patterns in distal left main coronary artery 88
Appraisal of key trials in aortic and mitral fields 88
Early discharge in acute myocardial infarction after clinical and angiographic risk assessment 87
Cyphering the mechanism of late failure of bioresorbable vascular scaffolds in percutaneous coronary intervention of the left main coronary artery 87
Antithrombotic pharmacotherapy after transcatheter aortic valve implantation: an update 87
Feasibility and Predictors of Early Discharge After Percutaneous Edge-to-Edge Mitral Valve Repair 87
Usefulness of 3D OCT to Diagnose a Noncircumferential Open-Cell Stent Fracture 86
Retrograde Approach for Chronic Total Occlusion Percutaneous Coronary Intervention: The Paradox of Choice 86
Prevention of Acute Kidney Injury with the RenalGuard System in patients undergoing Transcatheter Aortic Valve Implantation: The PROTECT-TAVI trial 86
Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for ostial/midshaft lesions in unprotected left main coronary artery from the DELTA registry: a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. 85
Bioresorbable vascular scaffold in patients with complex coronary artery disease. 84
Extended use of percutaneous edge-to-edge mitral valve repair beyond EVEREST (Endovascular Valve Edge-to-Edge Repair) criteria: 30-day and 12-month clinical and echocardiographic outcomes from the GRASP (Getting Reduction of Mitral Insufficiency by Percutaneous Clip Implantation) registry. 84
Management issues of chronic therapy with non-vitamin K oral anticolagulants or antiplatelet agents: different or alike? 83
Haemostatic Profiles Assessed by Thromboelastography in Patients with End-Stage Renal Disease 83
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: Results of the OPTIMUS-2 study 83
Transcatheter Aortic-Valve Replacement 82
Effects of Cangrelor in Coronary Artery Disease Patients With and Without Diabetes Mellitus: An In Vitro Pharmacodynamic Investigation 82
Late Self-Apposition With One-Year Persisting Uncoverage of Malapposed Bioresorbable Polymeric Struts 82
A Novel Mechanism by Which MitraClip Implantation May Favorably Alter the Natural History of Left Ventricular Remodeling in Patients with Mitral Regurgitation: Proposed Role of the Ventricular-Valvular Loop 82
Suitability for elderly with heart disease of a QR code-based feedback of drug intake: Overcoming limitations of current medication adherence telemonitoring systems 80
Is the metallic stent a safe treatment for bioresorbable scaffold failure? Insights from optical coherence tomography 80
Progresses in interventional cardiology: focus on patent foramen ovale, coronary intervention, antithrombotic pharmacology, and more 80
Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists 80
EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention 79
Update on clinical evidence (Part II): a summary of the main post market studies 79
Functional profile of the platelet P2Y12 receptor signaling pathway in patients with diabetes mellitus and coronary artery disease 78
Real world safety and efficacy of the janus tacrolimus-eluting stent: long-term clinical outcome and angiographic findings from the Tacrolimus-Eluting Stent (TEST) registry 78
Strategies and Outcomes of Repeat Mitral Valve Interventions After Failed MitraClip Therapy 78
Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: Development and internal validation of the PSP score 78
Transfemoral transcatheter aortic-valve replacement should be preferred over surgery in most intermediate-risk patients. 78
Short and mid-term benefits of coronary stent system with nanothin Polyzene-F in acute coronary syndromes: preliminary result 77
Risk stratification after ST-elevation myocardial infarction 76
Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device Iterations 75
Risk stratification for secondary prevention with ticagrelor and aspirin: a closer look to patient subsets from the PEGASUS-TIMI 54 trial 74
Treatment strategies for coronary in-stent restenosis: systematic review and hierarchical Bayesian network meta-analysis of 24 randomised trials and 4880 patients. 74
Percutaneous Coronary Intervention With Everolimus-Eluting Bioresorbable Vascular Scaffolds In Routine Clinical Practice: Early and Mid-Term Outcomes From The European Multicenter GHOST-EU Registry 74
Procedural management of patients with advanced heart failure undergoing MitraClip implantation (from the GRASP registry) 74
Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary PCI 74
Parenteral Anticoagulant Agents in PCI 74
Long-term clinical outcomes after drug-eluting stent implantation in unprotected left main coronary artery disease 74
MitraClip Implantation for the Treatment of New-Onset Systolic Anterior Motion of the Mitral Valve After Transcatheter Aortic Valve Replacement 74
Serum cotinine levels are associated with increased clopidogrel-induced antiplatelet effects 73
Meta-Analyses of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation: Do Bleeding and Stent Thrombosis Weigh Similar on Mortality? 73
One-Year Coverage by Optical Coherence Tomography of a Bioresorbable Scaffold Neocarina: Is It Safe to Discontinue Dual-Antiplatelet Therapy? 72
Mid-term clinical outcome of Catania coronary stent system with nanothin Polyzene-F in a real world unselected population: preliminary results 72
Early and Midterm Outcomes of Bioresorbable Scaffolds for Ostial Coronary Lesions: Insights from the GHOST-EU Registry 72
CABG Versus PCI In Diabetic Patients With Multivessel Disease After Risk Stratification By The SYNTAX Score: A Pooled Analysis Of The SYNTAX And FREEDOM Trials 72
Impact of Residual Platelet Reactivity on reperfusion in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention 72
Clinical development of selective anticoagulants: a state of the art 71
Simultaneous plaque rupture and erosion in the same atheroma: insights from two and three-dimensional optical coherence tomography 71
Capitolo 2 - Diagnostica cardiovascolare 71
Prasugrel: a novel platelet ADP P2Y(12) receptor antagonist. A review on its mechanism of action and clinical development 71
PHARMACODYNAMIC EFFECTS OF DIFFERENT ASPIRIN DOSING REGIMENS IN TYPE 2 DIABETES MELLITUS PATIENTS WITH CORONARY ARTERY DISEASE 71
Self-apposing STENTYS stent in acute myocardial infarction 71
Bioresorbable everolimus-eluting vascular scaffold for long coronary lesions: a subanalysis of the international, multi-center GHOST-EU registry 70
How true delivery profile diminution reduces vascular access challenges and complications 70
Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy 70
L'angioplastica complessa al posto del by-pass: ruolo degli score di rischio 70
Comparison of percutaneous coronary intervention (with drug-eluting stents) versus coronary artery bypass grafting in women with severe narrowing of the left main coronary artery (from the Women-Drug-Eluting stent for LefT main coronary Artery disease Registry) 70
Safety and effectiveness of the Catania Polyzene-F coated stent in real world clinical practice: 12-month results from the ATLANTA 2 registry 70
Percutaneous mitral valve repair with the MitraClip system for severe mitral regurgitation in patients with surgical mitral valve repair failure. 69
Percutaneous mitral valve repair with the MitraClip system in the elderly: One-year outcomes from the GRASP registry 69
Revascularization vs. Optimal Medical Therapy in Women with NSTE-ACS 69
Moderate and severe preoperative chronic kidney disease worsen clinical outcomes after transcatheter aortic valve implantation: meta-analysis of 4992 patients. 69
Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients 69
Plaque distribution patterns in distal left main coronary artery to predict outcomes after stent implantation 69
P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: A Network Meta-Analysis 68
Impact of direct oral anticoagulants on evolution of post-thrombotic syndrome 68
Antithrombotic Management of Elderly Patients With Coronary Artery Disease 68
Drug-Eluting Stent for Left Main Coronary Artery Disease: The DELTA Registry: A Multicenter Registry Evaluating Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Treatment 67
Long-term clinical outcome of diabetic patients treated with sirolimus-, paclitaxel- or zotarolimus-eluting stent 67
Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical practice: insights from the European multicenter GHOST-EU registry 67
Long-term outcomes after drug-eluting stent for the treatment of ostial left anterior descending coronary artery lesions 66
Totale 8.811
Categoria #
all - tutte 62.043
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 62.043


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021931 0 0 0 0 305 27 166 4 88 2 181 158
2021/20221.478 169 231 2 24 256 15 223 55 116 1 20 366
2022/20232.435 219 51 19 192 333 437 7 380 679 10 75 33
2023/20241.207 63 216 60 87 51 268 31 50 3 29 199 150
2024/20254.141 32 584 281 173 1.041 412 62 147 381 434 250 344
2025/20263.798 512 442 1.575 422 847 0 0 0 0 0 0 0
Totale 16.466